Καταχωρήθηκε: Πέμπτη 14 Απρ 2022

Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 25 mins

Hyperbilirubinemia occurs frequently after allogeneic stem cell transplantation. Causes include primary liver damage and
endothelial complications as major contributors. Here, we have investigated the impact of early bilirubinemia (EB) on
posttransplant outcomes. Maximum total bilirubin levels (days 0–28) were categorized using maximally selected log rank
statistics to identify a cut off for the endpoint non-relapse mortality (NRM) in a training cohort of 873 patients. EB above this cut
off was correlated with NRM and overall survival (OS) and with pre- and posttransplant Angiopoietin-2, interleukin (IL)18,
CXCL8 and suppressor of tumorigenicity-2 (ST2) serum levels, and the endothelial activation and stress index (EASIX). Clinical
correlations were validated in a sample of 388 patients transplanted in an independent institution. The EB cut off was determined
at 3.6 mg/dL (61.6 μM). EB predicted OS (HR 1.60, 95% CI 1.21–2.12, p < 0.001), and NRM (CSHR 2.14; 1.28–3.56, p =
0.004), also independent of typical endothelial complications such as veno-occlusive disease, refractory acute graft-versus-host disease, or transplant-associated microangiopathy. However, EB correlated with high Angiopoietin-2, EASIX-pre and EASIX- day 0, as well as increased levels of posttransplant CXCL8, IL18, and ST2. In summary, EB indicates a poor prognosis. The association of EB with endothelial biomarkers suggests an endothelial pathomechanism also for this posttransplant complication.


Τηλέφωνα Επικοινωνίας:


Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)


βρείτε μας στο χάρτη


Login / Sitemap


© Copyright 2015 - 2022 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας